Traditionally used as antidiabetic agents, SGLT2 inhibitors have demonstrated efficacy in slowing kidney disease progression and reducing the risk of end-stage renal disease (ESRD) in both type 2 DM (T2DM) and HFrEF patients, irrespective of diabetes status [8,9]. This evidence concerns the gene SLC5A2 and chronic kidney disease.